Main Article Content


Due to their global dominance as the most common opportunistic mycoses, Candida species are important in medicine. the commonness of C. The incidence of Candida albicans and other species has significantly increased over the past few decades. These studies looked examined the ability of a vulvovaginal sample to isolate and identify Candida species as well as how different antifungal drugs, such as Amphotericin B, Nystatin, Itraconazole, Clotrimazole, and Ketoconazole, affected different Candida strains. Thirty out of fifty non-pregnant women who visited Al-Zahra Hospital and displayed symptoms and signs of candidial vulvovaginitis had their vaginal Candida spp. collected. They were between 20 and 35 years old. Direct microscopic examination, mycological analysis, and plating on sabrouaud dextrose agar (SDA) were were performed on all vaginal swabs. SDA was then incubated for 48 hours at 37°C. The Candida isolates were identified to the spp. level using the Vitek 2 Compact System, growth morphology, germ tube tests, and conventional staining techniques. The findings revealed the presence of C. albicans (66.6%), C. tropicalis (26.6%), and C. krusei (6.6%). 


Candida Spp. , Candida albicans, Vulvovaginal Candidiasis

Article Details

How to Cite
Esraa Zeman Dayea. (2023). Isolation and Identification of Candida Spp. from non-pregnant Infection woman’s with Candidiasis . Medical Science Journal for Advance Research, 4(1), 23–27.


  1. J. D. Sobel, “Recurrent vulvovaginal candidiasis,” Am. J. Obstet. Gynecol., vol. 214, no. 1, pp. 15–21, 2016.
  2. D. W. Denning, M. Kneale, J. D. Sobel, and R. Rautemaa-Richardson, “Global burden of recurrent vulvovaginal candidiasis: a systematic review,” Lancet Infect. Dis., vol. 18, no. 11, pp. e339–e347, 2018.
  3. J. D. Sobel et al., “Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis,” N. Engl. J. Med., vol. 351, no. 9, pp. 876–883, 2004.
  4. A.-M. Rehab S and A.-A. Zouhair I, “Antifungal resistance of Candida species isolated from Iraqi women infected with vulvovaginal Candidiasis,” Al-Qadisiyah Med. J., vol. 7, no. 11, pp. 117–127, 2011.
  5. P. G. Pappas et al., “Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America,” Clin. Infect. Dis., vol. 62, no. 4, pp. e1–e50, 2016.
  6. S. Banaeian-Borujeni, G. R. Mobini, B. Pourgheysari, and M. Validi, “Comparison of the effect of honey and miconazole against Candida albicans in vitro,” Adv. Biomed. Res., vol. 2, 2013.
  7. A. A. Suhail and H. M. Samaka, “Effect of Fluconazole on HWP1 and PLB Genes Expression and Antifungal Resistant Status in Candida albicans,” NVEO-NATURAL VOLATILES Essent. OILS Journal| NVEO, pp. 1805–1815, 2021.
  8. R. Ben-Ami and D. P. Kontoyiannis, “Resistance to antifungal drugs,” Infect. Dis. Clin., vol. 35, no. 2, pp. 279–311, 2021.
  9. C. Klunk, E. Domingues, and K. Wiss, “An update on diaper dermatitis,” Clin. Dermatol., vol. 32, no. 4, pp. 477–487, 2014.
  10. S. S. Richter, R. P. Galask, S. A. Messer, R. J. Hollis, D. J. Diekema, and M. A. Pfaller, “Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases,” J. Clin. Microbiol., vol. 43, no. 5, pp. 2155–2162, 2005.
  11. D. W. Denning et al., “Delivering on antimicrobial resistance agenda not possible without improving fungal diagnostic capabilities,” Emerg. Infect. Dis., vol. 23, no. 2, p. 177, 2017.
  12. K. H. Das, V. Mangayarkarasi, and M. Sen, “Antifungal resistant in non-albicans candida species are emerging as a threat to antenatal women with vulvovaginal candidiasis,” Biomed. Pharmacol. J., vol. 12, no. 2, pp. 1369–1378, 2019.
  13. K. I. Othman, S. M. Abdullah, B. Ali, and M. Majid, “Isolation and identification Candida spp from urine and antifungal susceptibility test,” Iraqi J. Sci., pp. 1981–1988, 2018.
  14. N. A. Dakhiel and H. M. Samaka, “Comparative Evaluation Of Vitek 2 System And Pcr Technique In Identification Of Candida Species,” NVEO-NATURAL VOLATILES Essent. OILS Journal| NVEO, pp. 1621–1629, 2021.
  15. A. Bitew and Y. Abebaw, “Vulvovaginal candidiasis: species distribution of Candida and their antifungal susceptibility pattern,” BMC Womens. Health, vol. 18, no. 1, pp. 1–10, 2018.
  16. N. N. Raheem and K. K. Ghaima, “Antibiofilm Activity of Nystatin, Aspirin and EDTA Against Candida albicans Isolated from Iraqi Women with Vulvovaginitis.,” Medico-legal Updat., vol. 21, no. 1, 2021.